Development of CD96 antibodies for cancer treatment

开发用于癌症治疗的 CD96 抗体

• 批准号: nhmrc : 1093566
• 负责人: A/Pr John Miles
• 金额: $ 54.73万
• 依托单位: Queensland Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-cd96-antibodies-cancer-treatment/519443
• 关键词: Development; CD96; antibodies; cancer; treatment

There is an unmet medical need to develop new immunotherapies that are safer and potentially allow the treatment of a broader range of cancers. Inhibiting the immune checkpoint CD96 function represents an opportunity that may parallel and indeed complement the activity and impact of other lymphocyte checkpoint inhibitors in human cancer (eg. CTLA-4 and PD1/PD-L1). While developing a new human therapeutic antibody we will also learn more about an important checkpoint in the immune response.

在开发更安全、有可能治疗更广泛癌症的新型免疫疗法方面，还存在未得到满足的医疗需求。抑制免疫检查点CD96功能代表了一个机会，它可能与其他淋巴细胞检查点抑制剂在人类癌症中的活性和影响平行，甚至互补。CTLA-4和PD1/PD-L1)。在开发一种新的人类治疗性抗体的同时，我们也将更多地了解免疫反应中的一个重要检查点。